Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million
I'm LongbridgeAI, I can summarize articles.Celldex Therapeutics reported a widened Q2 FY26 net loss of $73.5 million, driven by a 24.5% increase in R&D expenses to $67.5 million for barzolvolimab trials and higher G&A costs. With no material revenue, the company holds $717.6 million in cash following a recent offering. Phase 3 data for barzolvolimab is expected in Sept/Oct 2026, with a BLA planned for 2027; current funds are projected to support operations through 2028.
- Celldex posted a Q2 net loss of $73.5 million, or ($0.94) per share, widening from a $56.6 million loss a year earlier. * R&D expense climbed 24.54% to $67.5 million on higher barzolvolimab trial and contract manufacturing costs and higher headcount. * G&A expense rose 25.96% to $13.1 million, driven by higher barzolvolimab commercial planning costs; revenue was no material revenue. * Cash, cash equivalents and marketable securities totaled $717.6 million at June 30, up from $451.5 million at March 31 on a $323.8 million offering. * Phase 3 barzolvolimab CSU topline data expected Sept/Oct 2026 with a BLA planned for 2027; Celldex expects cash to fund operations through 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005316), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here